The effect of nitric oxide on the production of cyclic AMP by a human osteoblast (HOS) cell line stimulated with hydroxyapatite.
The aim of the present study was to determine the effect of nitric oxide (NO) on the production of cyclic AMP (cAMP) by a human osteoblast cell line (HOS cells) stimulated with hydroxyapatite. Cells were cultured on the HA surfaces with or without the presence of NO donors (SNAP and NAP) for 3 days. The effect of adenylyl cyclase inhibitor (SQ22536), NO scavenger (carboxy PTIO) or endothelial nitric oxide synthase (eNOS) inhibitor (L-NIO), was assessed by adding these to the cultures of HA-stimulated HOS cells with or without the presence of SNAP. Furthermore, HOS cells were pre-treated with anti-human integrin alphaV antibody prior to culturing on HA surfaces with or without the presence of SNAP. The levels of cAMP and cGMP were determined from the 3-day culture supernatants. The results showed that the production of cAMP but not cGMP by HA-stimulated HOS cells was augmented by SNAP. SQ22536 and carboxy PTIO suppressed but L-NIO only partially inhibited the production of cAMP by HA-stimulated HOS cells with or without the presence of exogenous NO. Pre-treatment of the cells with anti-human integrin alphaV antibody suppressed the production of cAMP by HA-stimulated HOS cells with or without the presence of NO. Therefore, the results of the present study suggest that NO may up-regulate the production of cAMP, perhaps, by augmenting adenylyl cyclase activity initiated by the binding between HOS cell-derived integrin alphaV and HA surface.
Sosroseno
Wihaskoro
W
School of Dentistry, AIMST University, Amanjaya Campus, 2 Persiaran Cempaka, Sungai Petani 08000, Kedah Darul Aman, Malaysia. wsosroseno@yahoo.com
Sugiatno
Erwan
E
Samsudin
Abdul R
AR
Ibrahim
M Fikri
MF
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000067956:Adenylyl Cyclase Inhibitors; D000906:Antibodies / Q000494:pharmacology; D002460:Cell Line; D000242:Cyclic AMP / Q000096:biosynthesis*; D006152:Cyclic GMP / Q000096:biosynthesis; D003497:Cyclic N-Oxides / Q000494:pharmacology; D017886:Durapatite / Q000494:pharmacology*; D016166:Free Radical Scavengers / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D039564:Integrin alphaV / Q000276:immunology; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D052250:Nitric Oxide Synthase Type III / Q000037:antagonists & inhibitors; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D026423:S-Nitroso-N-Acetylpenicillamine / Q000494:pharmacology; D013268:Stimulation, Chemical
D000067956:Adenylyl Cyclase Inhibitors; D000906:Antibodies; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers; D007093:Imidazoles; D039564:Integrin alphaV; D020030:Nitric Oxide Donors; C017759:9-(tetrahydro-2-furyl)-adenine; C079391:2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; D009569:Nitric Oxide; C065027:N(G)-iminoethylornithine; D026423:S-Nitroso-N-Acetylpenicillamine; D017886:Durapatite; D000242:Cyclic AMP; D009952:Ornithine; D052250:Nitric Oxide Synthase Type III; D006152:Cyclic GMP; D000225:Adenine